2020
Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy
Eberly LA, Day SM, Ashley EA, Jacoby DL, Jefferies JL, Colan SD, Rossano JW, Semsarian C, Pereira AC, Olivotto I, Ingles J, Seidman CE, Channaoui N, Cirino AL, Han L, Ho CY, Lakdawala NK. Association of Race With Disease Expression and Clinical Outcomes Among Patients With Hypertrophic Cardiomyopathy. JAMA Cardiology 2020, 5: 83-91. PMID: 31799990, PMCID: PMC6902181, DOI: 10.1001/jamacardio.2019.4638.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAtrial FibrillationBlack or African AmericanCardiomyopathy, HypertrophicCohort StudiesDeath, Sudden, CardiacDefibrillators, ImplantableFemaleGenetic TestingHealth Services AccessibilityHealthcare DisparitiesHeart FailureHeart SeptumHeart TransplantationHeart-Assist DevicesHumansMaleMiddle AgedMortalityPhenotypeQuality of Health CareStrokeUnited StatesWhite PeopleConceptsNYHA class IIIAssociation of raceVentricular assist device implantationOverall composite outcomeSeptal reduction therapyAssist device implantationHeart failureBlack patientsHypertrophic cardiomyopathyCause mortalityWhite patientsAtrial fibrillationClass IIICardiac transplantationGenetic testingComposite outcomeClinical outcomesDisease expressionDevice implantationReduction therapyNew York Heart Association functional class IIIMultivariable Cox proportional hazards regressionInvasive septal reduction therapySarcomeric Human Cardiomyopathy RegistryImplantable cardioverter-defibrillator therapy
2018
Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial
Sharma A, Ambrosy AP, DeVore AD, Margulies KB, McNulty SE, Mentz RJ, Hernandez AF, Felker G, Cooper LB, Lala A, Vader J, Groake JD, Borlaug BA, Velazquez EJ. Liraglutide and weight loss among patients with advanced heart failure and a reduced ejection fraction: insights from the FIGHT trial. ESC Heart Failure 2018, 5: 1035-1043. PMID: 30120812, PMCID: PMC6300815, DOI: 10.1002/ehf2.12334.Peer-Reviewed Original ResearchConceptsWeight loss agentsHeart failureEjection fractionHF hospitalizationNew York Heart Association functional class IIIGlucagon-like peptide-1 (GLP-1) receptor antagonistHeart Failure Treatment studyWeight lossAcute HF hospitalizationEfficacy of liraglutideRecent HF hospitalizationFunctional class IIILast study visitReduced ejection fractionAdvanced heart failureCardiovascular outcome trialsMedian ejection fractionAnalysis of patientsLiraglutide useMultivariable adjustmentStudy drugObese patientsOutcome trialsMedian agePrimary outcome
2015
Does Age Influence Cardiac Resynchronization Therapy Use and Outcome?
Heidenreich PA, Tsai V, Bao H, Curtis J, Goldstein M, Curtis L, Hernandez A, Peterson P, Turakhia MP, Masoudi FA. Does Age Influence Cardiac Resynchronization Therapy Use and Outcome? JACC Heart Failure 2015, 3: 497-504. PMID: 25982109, DOI: 10.1016/j.jchf.2015.01.012.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionICD implantationOlder patientsTrial criteriaNew York Heart Association functional class IIIAge groupsSocial Security Death IndexPatients age 85Receipt of CRTFunctional class IIICardiac resynchronization therapyVentricular ejection fractionClinical trial criteriaDifferent age groupsPatient ageEjection fractionICD RegistryImproved survivalPrimary outcomeResynchronization therapyTherapy useDeath IndexMean ageClinical trialsRegistry data
2014
Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation Insights From the National Cardiovascular Data Registry
Hsu JC, Marcus GM, Al-Khatib SM, Wang Y, Curtis JP, Sood N, Parker MW, Kluger J, Lampert R, Russo AM. Predictors of an Inadequate Defibrillation Safety Margin at ICD Implantation Insights From the National Cardiovascular Data Registry. Journal Of The American College Of Cardiology 2014, 64: 256-264. PMID: 25034061, DOI: 10.1016/j.jacc.2014.01.085.Peer-Reviewed Original ResearchConceptsInadequate defibrillation safety marginDefibrillation safety marginSimple risk scoreAdverse eventsRisk scoreNew York Heart Association functional class IIIImplantable cardioverter defibrillator implantationNational Cardiovascular Data RegistrySecondary prevention indicationFunctional class IIIHospital adverse eventsCardioverter-defibrillator implantationIschemic heart diseaseLogistic regression modelsHospital mortalityPrevention indicationICD recipientsMale sexDefibrillation testingRenal dialysisHeart diseaseBiventricular deviceData registryLower riskGreater odds
2013
Risk Factors for Hospital Admission Among Older Persons With Newly Diagnosed Heart Failure Findings From the Cardiovascular Health Study
Chaudhry SI, McAvay G, Chen S, Whitson H, Newman AB, Krumholz HM, Gill TM. Risk Factors for Hospital Admission Among Older Persons With Newly Diagnosed Heart Failure Findings From the Cardiovascular Health Study. Journal Of The American College Of Cardiology 2013, 61: 635-642. PMID: 23391194, PMCID: PMC3576871, DOI: 10.1016/j.jacc.2012.11.027.Peer-Reviewed Original ResearchConceptsHeart failure diagnosisIndependent risk factorHospital admissionCardiovascular Health StudyHeart failureGeriatric conditionsRisk factorsMuscle weaknessSlow gaitOlder personsHealth StudyNew diagnosisNew York Heart Association functional class IIICommunity-living older personsDepressed ejection fractionHeart Failure FindingsFunctional class IIIChronic kidney diseaseCause hospital admissionsMedical record reviewRelevant clinical dataLong-term riskDiabetes mellitusEjection fractionKidney disease
1994
Mycarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus
Herskowitz A, Wu T, Willoughby S, Vlahov D, Ansari A, Beschorner W, Baughman K. Mycarditis and cardiotropic viral infection associated with severe left ventricular dysfunction in late-stage infection with human immunodeficiency virus. Journal Of The American College Of Cardiology 1994, 24: 1025-1032. PMID: 7930193, DOI: 10.1016/0735-1097(94)90865-6.Peer-Reviewed Original ResearchConceptsLeft ventricular dysfunctionCongestive heart failureEndomyocardial biopsy samplesVentricular dysfunctionHeart failureNew York Heart Association functional class IIIBiopsy samplesGlobal left ventricular hypokinesiaSevere left ventricular dysfunctionUnexplained left ventricular dysfunctionHuman immunodeficiency virus type 1Global left ventricular dysfunctionImmunodeficiency virus type 1Cardiotropic viral infectionCardiotropic virus infectionLeft ventricular hypokinesiaOpportunistic infectious agentFunctional class IIIHuman immunodeficiency virusHIV-1 gene sequencesNumber of patientsTwo-dimensional echocardiographyMajor histocompatibility class IVirus type 1Antisense riboprobes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply